On Tuesday, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. ASCVD is a chronic disease that occurs when plaque builds up in the walls of arteries, narrowing them and reducing blood flo